OLIVIER LICHTARGE to Cell Line, Tumor
This is a "connection" page, showing publications OLIVIER LICHTARGE has written about Cell Line, Tumor.
Connection Strength
0.348
-
Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled receptors expressed in tumors. Proc Natl Acad Sci U S A. 2021 12 21; 118(51).
Score: 0.115
-
Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Res. 2015 Apr 01; 75(7):1527-36.
Score: 0.071
-
MYC Induces Oncogenic Stress through RNA Decay and Ribonucleotide Catabolism in Breast Cancer. Cancer Discov. 2024 Sep 04; 14(9):1699-1716.
Score: 0.035
-
Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. Br J Cancer. 2023 06; 128(11):2013-2024.
Score: 0.031
-
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511.
Score: 0.022
-
Performance of in silico tools for the evaluation of p16INK4a (CDKN2A) variants in CAGI. Hum Mutat. 2017 09; 38(9):1042-1050.
Score: 0.021
-
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Res. 2015 Apr 01; 75(7):1205-15.
Score: 0.018
-
Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Mol Cancer Ther. 2015 Feb; 14(2):608-19.
Score: 0.018
-
Regulation of Ras localization and cell transformation by evolutionarily conserved palmitoyltransferases. Mol Cell Biol. 2014 Feb; 34(3):374-85.
Score: 0.016